Viridian Therapeutics (VRDN) Gets a Buy from RBC Capital
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Lisa Walter maintained a Buy rating on Viridian Therapeutics (VRDN) with a $35 price target, while shares closed at $18.79. Additionally, Wells Fargo's Derek Archila issued a new Buy rating today, contrasting with his previous Hold rating from June 17.
RBC Capital analyst Lisa Walter maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of $35.00. The company’s shares closed yesterday at $18.79.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Walter is a 4-star analyst with an average return of 10.3% and a 62.71% success rate. Walter covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, United Therapeutics, and Apellis Pharmaceuticals.
In addition to RBC Capital, Viridian Therapeutics also received a Buy from Wells Fargo’s Derek Archila in a report issued today. However, on June 17, Wells Fargo maintained a Hold rating on Viridian Therapeutics (NASDAQ: VRDN).